

Clinical Research Studies at CART Clinical Research Site , VHS-Infectious Diseases Medical Centre

Study:

A5175 - A Phase IV, Prospective, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily Protease Inhibitor- And Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations For Initial Treatment Of HIV-1 Infected Individuals From Resource-Limited Settings (PEARLS) Trial

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

ACTG/NIAID/NIH

Status:

Completed

Study:

A5199 -International Neurological Study- A Stand Alone Study for Participants of A5175 (A Phase IV, Randomized, Open-Label Evaluation of the Efficacy of Once Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Individuals from Diverse Areas of the World)

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

ACTG/NIAID/NIH

Status:

Completed

Study:

A5185 -Effect of Antiretroviral treatment of Genital Compartment virus in individuals initiating Potent Antiretroviral therapy from Resource limited settings.

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

ACTG/NIAID/NIH

Status:

Completed

Study:

A5207- Maintaining Options for Mothers Study (MOMS) – A Phase II Randomized Comparison of three Antiretroviral Strategies administered for 7 or 21 days to reduce the emergence of Nevirapine resistant HIV-1 following a single Intrapartum dose of Nevirapine

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

ACTG/NIAID/NIH

Status:

Completed

Study:

A5190- Assessment of Safety and Toxicity among Infants Born To HIV-1-Infected Women Enrolled in Antiretroviral Treatment Protocols in Diverse Areas of the World - A Limited Center Trial of the Adult AIDS Clinical Trials Group (AACTG) and the Pediatric AIDS Clinical Trials Group (PACTG), Conducted in Collaboration with the HIV Prevention Trials Network (HPTN)

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

ACTG/NIAID/NIH

Status:

Completed

Study:

A5221-STRIDE -A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis with CD4 < 250 Cells/mm³

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

ACTG/NIAID/NIH

Status:

Completed

Study:

A5230- A Pilot Study of Lopinavir/Ritonavir in Participants Experiencing Virologic Relapse on NNRTI-Containing Regimens

Principal Investigator:

Dr.N.Kumarasamy

Funding:

ACTG/NIAID/NIH

Status:

Completed

Study:

A5265 - A Phase III, Open-Label, Randomized, Assessment-Blinded Clinical Trial to Compare the Safety and Efficacy of Topical Gentian Violet to that of Nystatin Oral Suspension for the Treatment of Oropharyngeal Candidiasis in HIV-1 Infected Participants in Non-U.S. Settings

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

ACTG/NIAID/NIH

Status:

Completed

Study:

A5271- "Collection of Comparison Neurocognitive Data in Resource-Limited Settings"

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

ACTG/NIMH/NIAID/NIH

Status:

Completed

Study:

A5273:Multicenter Study of Options for SEcond-Line Effective Combination Therapy (SELECT) A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

ACTG/NIAID/NIH

Status:

Completed

Study:

A5274/REMEMBER- Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens A Site-Limited Trial of the AIDS Clinical Trials Group (ACTG)

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

ACTG/NIAID/NIH

Status:

Completed

Study:

HPTN 052-A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 In Serodiscordant Couples

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

HPTN/NIAD/NIH

Status:

Completed

Study:

A5288- Management Using the Latest Technologies in Resource-Limited Settings to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE)

Site Principal Investigator:

Dr.N.Kumarasamy

Status:

Completed

Study:

A5300/I2003-Study of MDR TB Cases and their Household Contacts: Operational Feasibility to inform PHOENIX Trial Design

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

ACTG/NIAID/NIH

Status:

Completed

Study:

START-INSIGHT PROTOCOL-Strategic Timing of Antiretroviral Treatment

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

INSIGHT/NIAID/NIH

Status:

Completed

Study:

Natural History of HIV disease in Southern India

Principal Investigator:

Dr.N.Kumarasamy

Funding:

Fogarty-Brown Univ/amFar/NIH

Status:

Study ongoing

Study:

TAHOD -The Treat Asia HIV Observational Database

Site Principal Investigator:

Dr.N.Kumarasamy

Collaborators:

Treat Asia

Funding: Treat Asia/amFar/leDEA/NIH

Status:

Study ongoing

Study:

TApHOD- The Treat Asia Pediatric HIV Observational Database

Site Principal Investigator:

Dr.N.Kumarasamy

Collaborators:

Treat Asia

Funding:

Treat Asia/amFar/NIH

Status:

Study ongoing

Study:

Optimizing HIV Care in Less Developed Countries

Site Principal Investigator:

Dr.N.Kumarasamy

Collaborators:

Dr.Kenneth Freedberg, Dr.Rochelle Walensky, Dr.Kennth Mayer-Harvard University

Funding:

CEPAC/MGH/NIH

Status:

Study ongoing

Study:

Randomized Control Trial of Structured Interrupted Generic Antiretroviral Therapy (SIT) versus Continuous Therapy (CT) in HIV-infected Individuals

Principal Investigators:

Dr.N.Kumarasamy, Dr.Timothy Flanigan, Dr.Kenneth Mayer

Collaborators:

Brown University

Funding:

Fogarty/Brown University/NIH

Status:

Completed

Study:

Prevalence and Incidence of Sexually Transmitted Infections among South Indians at Increased Risk of HIV Infection

Principal Investigators:

Dr.N.Kumarasamy, Dr.Kenneth Mayer

Collaborators:

Brown University

Funding:

Fogarty/Brown University/NIH

Status:

Completed

Study:

Correlates of ART Adherence in Chennai

Principal Investigators:

Dr.N.Kumarasamy, Dr.Steve Safren

Collaborators:

Fenway Centre,Boston;Brown University,RI

Funding:

Fogarty/Brown University, RI, USA

Status:

Completed

Study:

GSK TB 014 Project - A Phase II, Double Blind (Observer-Blind), Randomised, Controlled Study To Evaluate The Safety, Reactogenicity And Immunogenicity of GSK Biologicals' Candidate Tuberculosis Vaccine (M72/As01e) When Administered Intramuscularly According To A 0,1 Month Schedule To HIV-Positive Adults Living In A TB Endemic Region

Principal Investigator:

Dr.N.Kumarasamy

Funding:

GSK

Status:

Study Completed

Study:

AMC #054 - A Single-Arm, Open-Label Pilot Study of the Safety and Immunogenicity of the Merck Quadrivalent Human Papillomavirus Vaccine among HIV-Positive Women in India: A Trial of the AIDS Malignancy: Clinical Trials Consortium (AMC).

Principal Investigators:

Dr.N.Kumarasamy, Dr.Joel Palefsky, Dr.S.Poongulali

Coallborators:

UCSF,CA,USA

Funding:

AMC/NCI/Publications

Status:

Study Completed

Study:

SECONDLINE STUDY- A Randomised Open-Label Study comparing the Safety and Efficacy of Ritonavir boosted Lopinavir and 2-3N(T)RTI Backbone versus Ritonavir boosted Lopinavir and Raltegravir in Participants Virologically Failing First-Line NNRTI/2N(T)RTI Therapy

Principal Investigators:

Dr.N.Kumarasamy, Dr.Mark Boyd

Collaborators:

Kirby Institute, UNSW, Sydney

Funding:

Kirby Institute, UNSW, Sydney

Status: Completed

Study:

HIVIND - The Antiretroviral Roll out for HIV in India – Strengthening Capacity to Promote Adherence and Patient follow-up in the Context: A Research Plan for a Two-Centre, Randomized, Controlled, Open Trial in South India to Study an Innovative approach to Promote Adherence in HIV + Indian Patients

Principal Investigator:

Dr.N.Kumarasamy, Dr.Anita Shet, Dr.Vinod Diwan

Collaborators:

Karolinsk Institute, Sweden; St.Johns Medical Collge, Bangalore

Funding:

EU/ Karolinka Institute, Sweden

Status:

Study Completed.

Study:

WRHI001-GATES- A Randomized, Double-Blind, Multi-Centre, Parallel-Group Phase 3b Study To Demonstrate Non-Inferiority Of Stavudine (20 Mg Twice Daily) Compared With Tenofovir Disoproxil Fumarate (300 Mg Once Daily) When Administered In Combination With Lamivudine And Efavirenz In Anti Retroviral-Naive Patients Infected With HIV-1

Site Principal Investigator:

Dr.N.Kumarasamy

Collaborators:

Dr.Francois Venter, WITS, Johannesburg; Dr.Andrew Kambugu,IDI,Kampala

Funding:

Gates Foundation

Status:

Study Completed

Study:

K23- Impact of Malaria Co-Infection on HIV-Associated Neurocognitive Disorders

Principal Investigators:

Dr.N.Kumarasamy, Dr.Ajay Bharti

Collaborators:

UCSD, CA, USA

Funding:

CFAR/UCSD/NIH

Status:

Completed

Study:

REACH TIBOTECH: Malaria and HIV Co-infection in Southern India

Principal Investigators:

Dr.N.Kumarasamy, Dr.Ajay Bharti

Collaborators:

UCSD, CA, USA

Funding:

Tibotech

Study:

UNITE: A Randomized, Controlled Trial To Assess The Impact Of TAMA (Health ItSystem) On Treatment Effectiveness In HIV-1 Infected Subjects Initiated On First-Line Antiretroviral Therapy

Principal Investigators:

Dr.N.Kumarasamy, Dr.Anirudha Joshi

Funding:

Janssen

Status:

Study Completed

Study:

HIV Tropism study - A Multicenter, Cross-sectional Survey of HIV-1 Viral Co-receptor Tropism in Patients infected with Clade C HIV-1 at select sites in India

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Pfizer

Status:

Completed

Publications: Study group.The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa.J Int AIDS Soc. 2012 Jan 26;15(1):2.

Study:

A4001050- A Multi-Centre, Open Label, Expanded Access Trial of Maraviroc Site **Principal**

Investigator:

Dr.N.Kumarasamy

Funding:

Pfizer

Status:

Completed

Study:

ARIEL/TMC 114-TIDP29-C228-A Phase II, Open-Label Trial to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral activity of DRV in combination with Low Dose Ritonavir(DRV/RTV) in Treatment-experienced HIV-1 Infected Children from 3 Years to <6 Years of age

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Tibotec

Status:

Completed

Study:

Continued Access to Darunavir/Ritonavir (DRV/RTV) in HIV-1 Infected Children and Adolescents aged 3 Years and above (TMC114-TiDP29-C232), Protocol Amendment Gen-III, Issued Date October 9, 2012; Amendment Type: Non-Substantial

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Tibotec

Status:

Completed

Study:

TMC278-TiDP6-C215 - A Phase III, Randomized, Double-blind Trial Of TMC278 25 mg q.d. Versus Efavirenz 600 mg q.d. In Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors In Antiretroviral-Naive HIV-1 Infected Subjects

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Tibotec

Status:

Completed

Study:

ACH443-015 Achillion: A Phase II, Randomized, Blinded, 12-Week Comparison of Elvucitabine in Combination with Efavirenz and Tenofovir Versus Lamivudine in Combination with Efavirenz and Tenofovir in HIV-1 infected, Treatment-naïve Subjects, with an 84-Week Extension Treatment Period

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Achillion

Status:

Completed

Study:

Changes in HIV Viral Load in Patients Undergoing Treatment for Filarial Infection

Principal Investigators:

Dr.N.Kumarasamy, Dr.Tom Nutman, Dr.Sowmya Swaminathan

Collaborators:

NIRT, Chennai; LIP/NIAID/NIH

Funding:

NIAID/NIH

Status:

Completed

Study:

HIV resistance in India-HIV Drug Resistance in Blood and Genital Tract in India, Version 1.0, Version dated April 28, 2007

Principal Investigator:

Dr.N. Kumarasamy, Dr.Saravanan, Dr.Rami Kantor& Dr. Charles Carpenter

Funding:

CFAR/Brown University

Status:

Completed.

Study:

HIV and Ocular manifestations

Principal Investigators:

Dr.N.Kumarasamy, Dr.J.Biswas

Funding:

Sankara Nethralaya

Status:

Ongoing

Study:

HIV and Oral manifestations

Principal Investigators:

Dr.N.Kumarasamy, Dr.Ranganathan

Collaborators:

Ragas Dental College, Chennai Dental Research Foundation

Funding:

Ragas/Chennai Dental Research Foundation

Status:

Ongoing

Study:

Detection of Herpes viruses in Oral Fluids from HIV Positive patients in Chennai, India

Principal Investigators:

Dr.Ranganathan, Prof Newell W Johnson, Mr. David Speicher, Dr.Kumarasamy

Collaborators:

Ragas Dental College, Griffith University,Australia

Funding:

Australia

Status:

Completed

Study:

Impact of Alcohol on HIV transmission and ART adherence

Principal investigators:

Dr.N.Kumarasamy,Dr.Maria Ekstrand

Collaborators:

UCSF

Funding:

NIAAA/NIH

Status:

Completed

Study:

Immune Activation in Virologically Suppressed persons with HIV who are on ART

Principal Investigators:

Dr.N.Kumarasamy, Dr.Murugavel, Dr.Savita Pahwa

Collaborators:

University of Miami,Florida,USA

Funding:

ICMR/NIH

Status:

Study Completed

Study:

HPV Co-infection among HIV positive women in Chennai: A Pilot study

Principal Investigator:

Dr.Poongulali Selvamuthu, Dr.Lyn Menezes, Dr.N.Kumarasamy

Funding:

USF

Status:

Completed

Study:

Anemia and Nutrition among Children with Perinatally Acquired HIV Infection in South India

Principal Investigators:

Dr.Poongulali, Dr.Anita Shet, Dr.N.Kumarasamy

Collaborators:

St.Johns, Bangalore; NIRT, Chennai

Funding:

ICMR

Status:

Completed

Study:

HPV-019 PRI - A Phase IV, Observer-Blind, Randomized, Controlled, Multi centric Study to Assess the Safety and Immunogenicity of GSK Biologicals' HPV -16/18 L1 VLP AS04 Vaccine (Cervarix) Administered Intramuscularly According to A 3-Dose Schedule (Month

0, Week 6, Month 6) in Human Immunodeficiency Virus-Infected (HIV +) Female Subjects Aged 15-25 Years, as Compared to Merck's HVP 6/11/16/18 Vaccine (Gardasil)

Principal Investigators:

Dr.S.Poongulali, Dr.N.Kumarasamy,

Funding:

GSK

Status:

Study Completed

Study:

GIVCYT- Ganciclovir—Intravitreal Versus Systemic—Cytomegalovirus Retinitis Trial

Principal Investigators:

Dr.Jyotirmay Biswas, Dr.John Kempen, Dr.N.Kumarasamy, Dr. Sudharsan, Dr.S.Poongulali

Funding:

Sanakara Nethralaya

Status:

Completed

Study:

Menstrual Irregularities in Indian Women with HIV: Is immunologic status a factor?

Principal Investigators:

Dr.Poongulali Selvamuthu, Dr. Krutika Kuppali

Funding:

Observational

Status:

Completed

Study:

HAART associated body composition and metabolic changes in HIV infected patients in South India

Principal Investigators:

Dr.Suneetha Sagayam, Dr.Christine Wanke, Dr.N.Kumarasamy

Collaborators:

Brown University, Tufts University,USA

Funding:

Fogarty/Brown-Tufts Univ/NIH

Status: Completed

Study:

Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE (A5332)

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

NIH/National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases (NIAID)

Status:

Completed

Study:

Multicenter, non-randomized, non-controlled, open-label Phase IV trial to evaluate the safety, tolerability and Effectiveness of Dolutegravir 50 mg tablet of Emcure Pharmaceuticals along with other antiretrovirals among HIV-1 Infected participants', NARI/01-2017

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Emcure Pharmaceuticals Ltd

Status:

Completed

Study:

Open-Label Study with Rilpivirine in Treatment-naïve Indian Subjects With HIV-1 Infection to Determine Safety and Efficacy. RISE, Protocol TMC278HTX3001; Phase 3b

Principal Investigator:

Dr.N.Kumarasamy

Funding:

Johnson & Johnson Private Ltd

Status:

Completed

Study:

A phase IIIB/IV randomised open-label trial to compare dolutegravir + pharmaco-enhanced darunavir versus recommended standard of care antiretroviral regimens in patients with HIV infection who have failed recommended first line therapy, D2EFT: Dolutegravir and Darunavir Evaluation in adults Failing Therapy

Site Principal Investigators:

Dr. Poongulali.S and Dr.N.Kumarasamy

Funding:

UNITAID/University of New South Wales, The Kirby Institute, Australia

Status:

Completed

Study:

Understanding tobacco use and cessation among HIV-care individuals in India

Principal Investigators:

Dr. Gina Kruse and Dr. Poongulali.S

Funding:

NIH/NIAID-Harvard University Center for AIDS Research

Status:

Completed

Study:

Body Composition sub-study of D2EFT

Site Principal Investigator:

Dr.S.Poongulali

Funding:

University of New South Wales, The Kirby Institute, Australia

Status:

Completed

Study:

An International Observational Study of Outpatients with SARS-CoV-2 Infection INSIGHT 011:
International SARS-CoV-2 Infection Observational Study (ICOS)

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

University of Minnesota

Status:

Completed

Study:

COHIVE: Coronavirus Outcomes in HIV Evaluation in Resource Limited Settings
COVID-19 in people living with HIV: Evaluation of risk factors and outcomes in resource-limited settingsA pooled substudy of D2EFT

Site Principal Investigator:

Dr.S.Poongulali

Funding:

University of New South Wales, The Kirby Institute

Status:

Completed

Study:

A phase-III, multicenter, prospective, double blind, randomized, parallel clinical study evaluating the efficacy, safety and tolerability of hetero-tocilizumab in cytokine storm of severe coronavirus disease (covid-19) pneumonia (TOCICOVID study)

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Hetero Biopharma Limited

Status:

Completed

Study:

DASO-TBZ-2001 - Phase IIb Study to Evaluate the Efficacy and Safety of Sofosbuvir/Daclatasvir (SOF/DCV) with or without Nitazoxanide in Combination with Standard of Care in Adult Patients with Moderate Covid-19

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Mylan Laboratories Limited

Status:

Completed

Study:

"A randomized, double-blind, placebo-controlled, multicenter study of ensivibep (MP0420) in ambulatory adult patients with symptomatic COVID-19". The "EMPATHY" Trial

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Novartis Pharma AG

Status:

Completed

Study:

A Phase III, Multicentric, Prospective, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Molnupiravir in Adult Indian Patients with Mild COVID-19

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Hetero Labs Limited

Status:

Completed

Study:

A Phase III, Multicentric, Prospective, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Molnupiravir in Adult Indian Patients with Moderate COVID-19.

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Hetero Labs Limited

Status:

Completed

Study:

A Prospective, Randomized, Multicenter, Open Label, Parallel Group Study to Evaluate Safety and Efficacy of Oral Molnupiravir as Add on to Standard of Care for Treatment of Mild Patients with Covid-19 Disease (DRL-MOL-002)

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Dr. Reddy's Laboratories Limited

Status:

Completed

Study:

Public health emergency SOLIDARITY TRIAL World Health Organization COVID-19 core "An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are receiving the local standard of care

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

World Health Organization, Indian Council of Medical Research

Status:

Completed

Study:

INSIGHT Genomics Study INSIGHT -A substudy of qualifying INSIGHT studies

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

National Institute of Allergy and Infectious Diseases (NIAID),
National Institutes of Health (NIH)

Status:

Completed

Study :

WHO SOLIDARITY TRIAL PLUS "An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care"

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

World Health Organization, Indian Council of Medical Research

Status:

Completed

Study:

A Phase II, Multicenter, Randomized, Double Blind, Parallel, Placebo Controlled, Proof of Concept Study to Assess the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of HRF-10071 (Test Product, Manufactured by Hetero Labs Limited, India) in Antiretroviral Treatment-

naïve HIV Infected Patients. (HCR/II/HRF10071POC/10/2021).

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Hetero Labs Limited

Status:

Completed

Study:

Varenicline and mobile behavioral assistance for tobacco cessation in HIV care in India.

Site Principal Investigator:

Dr.S.Poongulali

Funding:

National Cancer Institute, National Institute of Health

Status:

Ongoing

Study:

ACTIV-2d/A5407-A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID 19

Site Principal Investigator:

Dr.S.Poongulali

Funding:

Shionogi, National Institute of Allergy and Infectious Diseases (NIH), Division of AIDS (DAIDS)

Status:

Completed

Study:

A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA).

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

AstraZeneca Pharma India Ltd

Status:

Ongoing

Study:

HCR/II/HRF10071POCEXT/09/2022 - A Phase IIa, Multicenter, Randomized, Double Blind, Parallel, Placebo Controlled, Proof of Concept Study to Assess the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of HRF-10071(Test Product, Manufactured by Hetero Labs Limited, India) 80mg & 120mg Tablets Once Daily Orally in Antiretroviral Treatment-naïve HIV Infected Patients

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Hetero Labs Limited

Status:

Completed

Study:

BSV L-AMB 21 04 - A Prospective, Multi-centre, Active Post-Marketing Surveillance Study of Liposomal Amphotericin B (Amphonex® - Manufactured by Bharat serums and Vaccines Ltd) in Patients with Invasive Fungal infection who are refractory to or intolerant of conventional Amphotericin B therapy in Real World Clinical Practice (AMBeR)

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Bharat Serums and Vaccines Ltd

Status:

Ongoing

Study:

CEYU688A12201 - A randomized, participant- and investigator-blinded, Placebo - controlled, parallel group study to assess the efficacy, safety and pharmacokinetics of EYU688 in patients with dengue fever.

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Novartis Healthcare Private Limited

Status:

Ongoing

Study:

Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1)

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

GSK Research & Development Limited

Status:

Ongoing

Study :

MC/ZOS/23-012 - Disease Burden and Healthcare Utilization Among Adult Patients with Herpes Zoster in India: A Multicentric, Hospital-Based, Prospective, Observational Study.

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Medclin Research Pvt. Ltd.

Status:

Ongoing

Study:

HIV-1 subtype-specific drug resistance in patients failing dolutegravir-based first-line, second-line or third-line regimens: multiregional study.

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

The U.S. National Institutes of Health

Status:

Completed

Study:

Global Long-acting Drug Combination Development (GLAD) Project: Preferred User Characteristics Evaluation.

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

Unitaid/WHO Geneva, Switzerland

Status:

Ongoing

Study:

A Phase III/IV factorial randomised double-blind trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin/ezetimibe versus pitavastatin, in patients with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk (the OPTIMAR study). OPTImising Metabolic management on Integrase based ART (OPTIMAR)

Site Principal Investigator:

Dr.N.Kumarasamy

Funding:

The Kirby Institute, University of NSW, New South Wales, Australia

Status:

Ongoing
